Zakko Liam, Lutzke Lori, Wang Kenneth K
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA -
Minerva Med. 2017 Feb;108(1):28-42. doi: 10.23736/S0026-4806.16.04864-3. Epub 2016 Oct 28.
Barrett's esophagus is the only known esophageal precursor for the development of esophageal adenocarcinoma. However, screening for Barrett's esophagus remains controversial. Although screening is advocated in selected populations, it is unclear how it should be implemented. In this review, the current definition of Barrett's esophagus will be discussed. There will be a review of the emerging evidence supporting the cost-effectiveness of screening and surveillance for Barrett's esophagus in preventing esophageal adenocarcinoma. The known risk factors for Barrett's esophagus and the development of esophageal adenocarcinoma, currently utilized to determine the appropriate populations to screen, will be reviewed. Finally we will review the standard techniques utilized to screen for Barrett's esophagus and examine new technologies that might improve the efficacy and availability of Barrett's esophagus screening.
巴雷特食管是已知的食管腺癌唯一的食管前驱病变。然而,巴雷特食管的筛查仍存在争议。尽管在特定人群中提倡进行筛查,但尚不清楚应如何实施。在本综述中,将讨论巴雷特食管的当前定义。还将回顾支持巴雷特食管筛查和监测在预防食管腺癌方面成本效益的新证据。将回顾目前用于确定合适筛查人群的巴雷特食管及食管腺癌发生的已知危险因素。最后,我们将回顾用于筛查巴雷特食管的标准技术,并研究可能提高巴雷特食管筛查效果和可及性的新技术。